Erythropoietic agents for anemia of critical illness

American Journal of Health-System Pharmacy

Volumn 65, Issue 6, 2008, Pages 540-546

  Shermock, Kenneth M ^a,d   Horn, Ed ^b   Rice, Ted L ^c,d  

^a Center for Pharmaceutical Outcomes and Policy   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Anemia; Blood; Costs; Critical illness; Economics; Epoetin alfa; Hematopoietic agents; Thromboembolism; Toxicity

Indexed keywords

IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; OXYGEN;

ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; BLOOD; COST BENEFIT ANALYSIS; CRITICAL ILLNESS; ECONOMICS; ERYTHROCYTE TRANSFUSION; INTENSIVE CARE; INTENSIVE CARE UNIT; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ANEMIA; COST-BENEFIT ANALYSIS; CRITICAL CARE; CRITICAL ILLNESS; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; HEMATINICS; HUMANS; INTENSIVE CARE UNITS; OXYGEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM;

EID: 41049085368     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070225     Document Type: Review

References (50)

1. Bateman NT, Leach RM. ABC of oxygen: acute oxygen therapy. BMJ. 1998; 317:798-801.
2. Corwin HL, Gettinger A, Pearl RG et al. The CRIT study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med. 2004; 32:39-52.
3. Rudis MI, Jacobi J, Hassan E et al. Managing anemia in the critically ill patient. Pharmacotherapy. 2004; 24:229-47.
4. Vincent JL, Baron JF, Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002; 288: 1499-507.
5. Weg JG. Oxygen transport in adult respiratory distress syndrome and other acute circulatory problems: relationship of oxygen delivery and oxygen consumption. Crit Care Med. 1991; 19:650-7.
6. Hebert PC, Tinmouth A, Corwin HL. Controversies in RBC transfusion in the critically ill. Chest. 2007; 131:1583-90.
7. Claessens YE, Fontenay M, Pene F et al. Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock. Am J Respir Crit Care Med. 2006; 174:51-7.
8. Pieracci FM, Barie PS. Diagnosis and management of iron-related anemias in critical illness. Crit Care Med. 2006; 34:1898-905.
9. Nguyen BV, Bota DP, Melot C et al. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med. 2003; 31:406-10.
10. Corwin HL, Gettinger A, Rodriguez RM et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999; 27:2346-50.
11. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA. 2002; 288:2827-35.
12. Corwin HL, Gettinger A, Fabian TC et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007; 357:965-76.
13. MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health. 2005; 8:105-16.
14. Shermock KM, Horn E, Lipsett PA et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med. 2005; 33:497-503.
15. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999; 340:409-17.
16. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345:1368-77.
17. Red blood cell transfusions contaminated with Yersinia enterocolitica - United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR Morb Mortal Wkly Rep. 1997; 46:553-5.
18. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002; 42:975-9.
19. Goodnough LT. Risks of blood transfusion. Crit Care Med. 2003; 31(suppl 12):S678-86.
20. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North Am. 2005; 23:241-52.
21. Kuehnert MJ, Roth VR, Haley NR et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001; 41:1493-9.
22. Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities. Transfusion. 1997; 37:243-4.
23. Linden JV, Wagner K, Voytovich AE et al. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion. 2000; 40:1207-13.
24. Ness PM, Shirey RS, Thoman SK et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion. 1990; 30:688-93.
25. Popovsky MA, Chaplin HC, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion. 1992; 32:589-92.
26. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985; 25:573-7.
27. Offner PJ, Moore EE, Biffl WL et al. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002; 137:711-6.
28. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest. 2005; 127:295-307.
29. Taylor RW, Manganaro L, O'Brien J et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002; 30:2249-54.
30. McCarthy LJ. How do I manage a blood shortage in a transfusion service? Transfusion. 2007; 47:760-2.
31. Sullivan MT, Cotten R, Read EJ et al. Blood collection and transfusion in the United States in 2001. Transfusion. 2007; 47:385-94.
32. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005; 45:141-8.
33. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993; 269:3024-9.
34. Lieberman JA, Weiskopf RB, Kelley SD et al. Critical oxygen delivery in conscious humans is less than 7.3 mL 02 x kg(-1) x min(-1). Anesthesiology. 2000; 92:407-13.
35. Weiskopf RB, Viele MK, Feiner J et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998; 279:217-21.
36. Carson JL, Duff A, Poses RM et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996; 348:1055-60.
37. Wu WC, Rathore SS, Wang Y et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230-6.
38. Carson JL. Should patients in intensive care units receive erythropoietin? JAMA. 2002; 288:2884-6. Editorial.
39. Yusuf S, Wittes J, Probstfield et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266:93-8.
40. Zarychanski R, Turgeon AF, McIntyre L et al. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ. 2007; 177:725-34.
41. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford Medical Publications; 1997.
42. Gold MR, Siegel JE, Russell LB et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
43. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276:1172-7.
44. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8.
45. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977; 296:716-21.
46. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med. 1999; 130:857-8.
47. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. JAMA. 1995; 273:1610-3.
48. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965; 58:295-300.
49. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med. 2007; 356:1705-7.
50. Szklo M, Nieto FJ. Epidemiology: beyond the basics. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers; 2007.